Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)

China flag China · Delayed Price · Currency is CNY
57.56
+5.56 (10.69%)
At close: May 21, 2026
Market Cap26.77B +9.0%
Revenue (ttm)894.02M +104.0%
Net Income-667.09M
EPS-1.46
Shares Out465.17M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume10,080,340
Average Volume3,966,109
Open52.20
Previous Close52.00
Day's Range52.20 - 60.74
52-Week Range46.66 - 86.18
Beta0.01
RSI55.77
Earnings DateApr 30, 2026

About SHA:688192

Dizal (Jiangsu) Pharmaceutical Co., Ltd., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of oncology and hematologic disorders. Its assets include the ZEGFROVY, for the treatment of solid tumors; Gao Ruizhe to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematological malignancy and solid tumors. Dizal (Jiangsu) Pharmaceutical Co., L... [Read more]

Sector Healthcare
Founded 2017
Employees 1,009
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688192
Full Company Profile

Financial Performance

In 2025, SHA:688192's revenue was 801.14 million, an increase of 122.60% compared to the previous year's 359.90 million. Losses were -764.05 million, -9.68% less than in 2024.

Financial Statements